Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Corporate Update (May 2026)
19 slides from Pyc Therapeutics's corporate update, May 22, 2026
Slide 1: Life-changing science: 2026 Q2 Investor Webinar
For personal use only Life-changing science 2026 Q2 Investor Webinar May 2026
Slide 2: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business of PYC Therapeutics about the future, you are urged to view all forward looking statements contained in this For personal use only Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only
Slide 3: Agenda for today
Agenda for today For personal use only • Introduction to PYC • Overview of the forward development plan for the company’s pipeline programs • Program-specific updates and immediate objectives • Q&A PYC THERAPEUTICS 3
Slide 4: PYC's mission is to create life-changing RNA therapies
For personal use only PYC’s mission is to create life-changing RNA therapies that address the root cause of diseases resulting from insufficient gene expression The Company’s work is dedicated to patients who currently have no treatment options available Sierra – living with Phelan- McDermid Syndrom
Slide 5: PYC designs RNA therapies to increase gene expression in haploinsufficiency
PYC designs RNA therapies to increase gene expression in diseases caused by haploinsufficiency For personal use only There are two copies of One copy of a gene is PYC’s drug candidates leverage every gene in humans non-functional in a the ‘good’ copy of the gene to haploinsufficiency restore express
Slide 6: PYC has built a pipeline of drug candidates with disease-modifying potential
PYC has built a pipeline of drug candidates with disease- modifying potential in large indications Progress expected in 20251 For personal use only Program Pre-clinical Clinical Market Size1 Phase 1/2 Registrational PYC-003 Polycystic Kidney Disease US$10bn p.a. PYC-002 Phelan-McDermid Syndrome US$5
Slide 7: PYC is focused on delivering near-term human Proof of Concept read-outs
PYC is focused on delivering near-term human Proof of Concept (PoC) read-outs for its pipeline of drug candidates For personal use only Commandment #10 - “The world belongs to finishers” Finishing requires focus: pick a few things and deliver on them. In drug discovery, it’s always easier to “turn o
Slide 8: For personal use only
For personal use only 1. Stifel: Building value in biotech 26 February 2024 PYC THERAPEUTICS 8
Slide 9: Multiple human safety and efficacy read-outs expected within the next 18 months
PYC has multiple human safety and efficacy read-outs expected within the next 18 months1 For personal use only Program 2026 2027 2028 2029 2030 PYC-003 Phase 1a/1b Studies 1 2 Registrational trials Polycystic Kidney Disease (PKD) 12-month data on Registrational efficacy registrational endpoint (TKV)
Slide 10: The Company has arrived at the 'turning of the cards'
The Company has arrived at the ‘turning of the cards’ For personal use only Commandment #8 - “I’m from Missouri… show me data”. As he says, “the coinage of the realm is data” so spare the hand-waving talk, wordy powerpoints, and show the data, “gleamed both at the bench but also occasionally in hard
Slide 11: PKD program
For personal use only Life-changing science PKD program May 2026
Slide 12: Immediate objective in PKD is clinical proof of concept on the registrational endpoint
PYC’s immediate objective in PKD is to demonstrate clinical proof of concept on the registrational endpoint Progress to date For personal use only Combined Phase 1a/1b Study2 Phase 2/3 Study Part A - SAD in healthy Part B – SAD in ADPKD Part C – MAD in Registrational study Confirmatory extension vol
Slide 13: PMS program
For personal use only Life-changing science PMS program May 2026
Slide 14: The Company's PMS program is preparing to enter the clinic
The Company’s PMS program is preparing to enter the clinic For personal use only Commandment #7 - “Find the shortest route to heaven”. In discovery, don’t spend years doing every preclinical pharmacology model – do a few, not half- a-dozen or more – and then with confidence sprint quickly to the dru
Slide 15: Immediate objective in PMS is to complete GLP toxicology studies
PYC’s immediate objective in PMS is to complete GLP toxicology studies enabling ‘first in human’ trials to commence Progress to date Pre-clinical studies GLP. PK and Toxicology Studies Clinical Trials For personal use only For this combination of: • Chemistry: 2′MOE PS3 Clinical validation of this m
Slide 16: Ophthalmology programs
For personal use only Life-changing science Ophthalmology programs May 2026
Slide 17: Immediate objective in the ADOA program is clinical proof of concept
PYC’s immediate objective in the ADOA program is to demonstrate ‘clinical proof of concept’ Progress to date For personal use only Phase 1a SAD Study Phase 1b MAD Study2 Phase 2/3 Study Cohorts 60 mcg 60 mcg (Q12W) Objectives of Phase 1/2/3 trials of PYC-001 • Safety & Tolerability • Efficacy 30 mcg
Slide 18: Immediate objective in the RP11 program is to define the path to an NDA
PYC’s immediate objective in the RP11 program is to define the path to an NDA For personal use only Progress to date Open Phase 1a SAD Label Phase 1b MAD Study Phase 2/3 Study Extension • Safety & Tolerability FDA Type D • Safety & Tolerability NDA • Efficacy • Efficacy meeting • Primary: • Low-Lumi
Slide 19: Q&A
For personal use only Life-changing science Q&A May 2026